Protagonist Therapeutics, Inc.

NasdaqGM:PTGX Stock Report

Market Cap: US$5.1b

Protagonist Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:PTGX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
27 Jan 26SellUS$1,513,397Asif AliIndividual18,203US$83.14
23 Jan 26SellUS$1,083,905Arturo MolinaIndividual13,151US$82.42
20 Jan 26SellUS$2,840,446Dinesh PatelIndividual34,438US$82.48
20 Jan 26SellUS$708,338Asif AliIndividual8,588US$82.48
20 Jan 26SellUS$784,715Arturo MolinaIndividual9,514US$82.48
17 Nov 25SellUS$229,896Arturo MolinaIndividual2,712US$84.77
25 Jul 25SellUS$570,534Dinesh PatelIndividual10,415US$54.78
23 Jul 25SellUS$2,880,044Dinesh PatelIndividual52,444US$55.05
22 Apr 25SellUS$80,776Asif AliIndividual1,756US$46.00
19 Feb 25SellUS$204,607Dinesh PatelIndividual5,359US$38.18

Insider Trading Volume

Insider Buying: PTGX insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of PTGX?
Owner TypeNumber of SharesOwnership Percentage
State or Government26,4900.0354%
Individual Insiders676,5480.903%
Hedge Funds12,004,29016%
Institutions62,218,97383%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 90.31% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.5%
BlackRock, Inc.
9,715,966US$791.8m3.32%0.01%
9.99%
Farallon Capital Management, L.L.C.
6,248,013US$509.2m0.84%2.8%
9.21%
RTW Investments, LP
5,756,277US$469.1m0%5.52%
8.66%
The Vanguard Group, Inc.
5,413,690US$441.2m27.2%0.01%
5.07%
Wellington Management Group LLP
3,171,423US$258.4m66.2%0.04%
5.06%
State Street Global Advisors, Inc.
3,165,795US$258.0m-1.3%0.01%
4.6%
UBS Asset Management AG
2,874,549US$234.2m43.3%0.02%
4.1%
BVF Partners L.P.
2,560,916US$208.7m-20.3%5.82%
3.92%
Johnson & Johnson Innovation - JJDC, Inc.
2,449,183US$199.6m0%36.16%
2.32%
Geode Capital Management, LLC
1,452,928US$118.4m2.56%0.01%
2.3%
Woodline Partners LP
1,438,247US$117.2m51.9%0.53%
1.95%
T. Rowe Price Group, Inc.
1,220,436US$99.5m30.3%0.01%
1.82%
Driehaus Capital Management LLC
1,139,854US$92.9m50.4%0.43%
1.76%
Janus Henderson Group plc
1,100,821US$89.7m146%0.03%
1.74%
Marshall Wace LLP
1,085,564US$88.5m0%0.11%
1.65%
Perceptive Advisors LLC
1,030,134US$83.9m-4.12%1.89%
1.64%
Commodore Capital LP
1,025,000US$83.5m-4.65%3.32%
1.58%
ADAR1 Capital Management, LLC
989,182US$80.6m4.34%7.38%
1.25%
Bank of America Corporation
779,210US$63.5m-2.68%0.02%
1.15%
Adage Capital Management, L.P.
718,202US$58.5m-34.3%0.09%
1.12%
Lynx1 Capital Management LP
700,014US$57.0m-4.5%11.0%
1.05%
The Goldman Sachs Group, Inc.
654,697US$53.4m13%0.02%
0.96%
Northern Trust Global Investments
603,222US$49.2m-1.93%0.01%
0.95%
Morgan Stanley
593,039US$48.3m-15.2%no data
0.91%
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.
571,825US$46.6m0%0.25%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/15 12:03
End of Day Share Price 2026/02/13 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Protagonist Therapeutics, Inc. is covered by 22 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Mayur SomaiyaBMO Capital Markets Equity Research
Evan SeigermanBMO Capital Markets Equity Research